Showing results (1251-1260 of 1,351) with videos related to
Sort By:
Pageof 136
Physical Review Letters|June 13, 2009
Gamma-ray spectroscopy at the limits: first observation of rotational bands in 255LrS Ketelhut, P T Greenlees, D Ackermann, et al.Physical Review Letters|June 17, 2017
Anomalies in the Charge Yields of Fission Fragments from the ^{238}U(n,f) ReactionJ N Wilson, M Lebois, L Qi, et al.Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.The New England Journal of Medicine|June 2, 2025
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaDanny Rischin, Sandro Porceddu, Fiona Day, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 14, 2013
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma"Annette Pflugfelder, Corinna Kochs, Andreas Blum, et al.Nature Communications|January 17, 2025
Discordance, accuracy and reproducibility study of pathologists' diagnosis of melanoma and melanocytic tumorsSarah Haggenmüller, Christoph Wies, Julia Abels, et al.Physical Review Letters|October 10, 2015
Decay and Fission Hindrance of Two- and Four-Quasiparticle K Isomers in ^{254}RfH M David, J Chen, D Seweryniak, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 16, 2023
S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and preventionUlrike Leiter, Markus V Heppt, Theresa Steeb, et al.Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.Pageof 136